Anurag Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anurag Gupta has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Satyendra Kumar Singh
Stem Cell/ Cell Culture Lab, Centre for Advance Research, King George`S Medical University, Lucknow, India
2 shared publications - Vijay Kumar
Department of Surgical Oncology, King’s George Medical University, Lucknow, India
2 shared publications - Abhilasha Tripathi
Department of Pharmacology King George's Medical University Lucknow India
1 shared publication - Anjana Singh
Department of Pulmonary and Critical Care Medicine, King George's Medical University, Lucknow 226 003, India
1 shared publication - Arun Chaturvedi
Department of Surgical Oncology, King George’s Medical University, Lucknow, India
1 shared publication - Dharmendra Kumar
Stem Cell/ Cell Culture Lab, Centre for Advance Research, King George`S Medical University, Lucknow, India
1 shared publication
Latest Publications
- 29 January 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (4) , 1661-1676
Stress-specific expression of HSPA and DNAJ chaperones regulated by NRF2/HSF1 in neurodegenerative conditions
- 29 January 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (4) , 1661-1676
Stress-specific expression of HSPA and DNAJ chaperones regulated by NRF2/HSF1 in neurodegenerative conditions
- 7 November 2025
- Published by Springer Nature in Head and Neck Pathology
- Vol. 19 (1) , 1-17
Association of Epithelial to Mesenchymal transition Markers on Prognosis and Clinicopathological Characteristics in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Background Oral squamous cell carcinoma (OSCC) is the most common oral malignancy, often associated with poor outcomes due to metastasis and late detection. The epithelial-to-mesenchymal transition (EMT) is central to OSCC progression, but the prognostic role of EMT markers remains unclear. This systematic review and meta-analysis evaluated five key EMT markers-E-cadherin, EpCAM, Vimentin, TWIST, and SNAIL-in OSCC. Methods Following PRISMA guidelines, studies were retrieved from PubMed, Scopus, Embase, ClinicalTrials.gov, and Google Scholar up to May 2025. Pooled odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) were calculated using RevMan 5.4.1 Heterogeneity was assessed by the I2 index, and fixed- or random-effects models were applied. Results Seventy-three observational studies were included. Vimentin showed the strongest prognostic effect, being significantly associated with lymph node metastasis (OR = 11.84, 95% CI 7.56–18.53, p < 0.00001), advanced TNM stage (OR = 6.88, p < 0.00001), poor differentiation (OR = 7.37, p < 0.00001), and poor overall survival (HR = 5.09, p < 0.00001). TWIST (HR = 4.96, p < 0.00001) and SNAIL (HR = 2.06, p = 0.0003) were also strongly predictive of aggressive clinicopathological features and worse survival. Loss of E-cadherin correlated with poor differentiation (OR = 2.80, p < 0.00001) and reduced disease-free survival (RR = 0.80, p = 0.0005), though its effect on overall survival was inconsistent. EpCAM expression showed context-dependent roles, with high expression linked to advanced stage and poor OS, whereas low expression predicted poor differentiation. Overall, Vimentin and TWIST consistently emerged as the strongest predictors of adverse outcomes, while preserved E-cadherin was protective. Conclusion Vimentin, TWIST, and SNAIL are strong predictors of aggressive disease and poor survival in OSCC, while preserved E-cadherin is protective. EMT markers hold promise for prognostic assessment and precision management in OSCC. Graphical abstract
- 7 November 2025
- Published by Springer Nature in Head and Neck Pathology
- Vol. 19 (1) , 1-17
Association of Epithelial to Mesenchymal transition Markers on Prognosis and Clinicopathological Characteristics in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Background Oral squamous cell carcinoma (OSCC) is the most common oral malignancy, often associated with poor outcomes due to metastasis and late detection. The epithelial-to-mesenchymal transition (EMT) is central to OSCC progression, but the prognostic role of EMT markers remains unclear. This systematic review and meta-analysis evaluated five key EMT markers-E-cadherin, EpCAM, Vimentin, TWIST, and SNAIL-in OSCC. Methods Following PRISMA guidelines, studies were retrieved from PubMed, Scopus, Embase, ClinicalTrials.gov, and Google Scholar up to May 2025. Pooled odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) were calculated using RevMan 5.4.1 Heterogeneity was assessed by the I2 index, and fixed- or random-effects models were applied. Results Seventy-three observational studies were included. Vimentin showed the strongest prognostic effect, being significantly associated with lymph node metastasis (OR = 11.84, 95% CI 7.56–18.53, p < 0.00001), advanced TNM stage (OR = 6.88, p < 0.00001), poor differentiation (OR = 7.37, p < 0.00001), and poor overall survival (HR = 5.09, p < 0.00001). TWIST (HR = 4.96, p < 0.00001) and SNAIL (HR = 2.06, p = 0.0003) were also strongly predictive of aggressive clinicopathological features and worse survival. Loss of E-cadherin correlated with poor differentiation (OR = 2.80, p < 0.00001) and reduced disease-free survival (RR = 0.80, p = 0.0005), though its effect on overall survival was inconsistent. EpCAM expression showed context-dependent roles, with high expression linked to advanced stage and poor OS, whereas low expression predicted poor differentiation. Overall, Vimentin and TWIST consistently emerged as the strongest predictors of adverse outcomes, while preserved E-cadherin was protective. Conclusion Vimentin, TWIST, and SNAIL are strong predictors of aggressive disease and poor survival in OSCC, while preserved E-cadherin is protective. EMT markers hold promise for prognostic assessment and precision management in OSCC. Graphical abstract
- Open Access
- 1 June 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 4519-4530
Mitochondrial Stress–Mediated Targeting of Quiescent Cancer Stem Cells in Oral Squamous Cell Carcinoma
Introduction: Despite improved therapeutics in oral squamous cell carcinoma (OSCC), tumor cells that are either quiescent and/or endowed with stem cell–like attributes usually survive treatment and recreate tumor load at relapse. Through this study, we aimed strategically to eliminate these stem cell–like cancer cells using a combination drug approach. Methods: Primary cultures from 15 well–moderately differentiated OSCC were established, and the existence of cancer cells with stem cell–like characteristics using five cancer stem cell (CSC) specific markers — CD44, CD133, CD147, C166, SOX2 and spheroid assay was ascertained. Next, we assessed quiescence in CSCs under normal and growth factor–deprived conditions using Ki67. Among several gene signatures regulating quiescent cellular state, we evaluated the effect of inhibiting Dyrk1b in combination with topoisomerase II and histone deacetylase inhibitors in targeting quiescent CSCs. Multiple drug-effect analysis was carried out with CompuSyn software to determine combination-index values. Results: We observed that CD44+CD133+ showed the highest level of SOX2 expression. CSCs showed varying degrees of quiescence, and inhibition of Dyrk1b decreased quiescence and sensitized CSCs to apoptosis. In the drug-combination study, Dyrk1b inhibitor was combined with topoisomerase II and histone deacetylase inhibitors to target quiescent CSCs. In combination, a synergistic effect was seen even at a 16-fold lower dose than IC50. Furthermore, combined treatment decreased glutathione levels and increased ROS and mitochondrial stress, leading to increased DNA damage and cytochrome c in CSCs. Conclusion: We report marker-based identification of CSC subpopulations and synergy of Dyrk1b inhibitor with topoisomerase II and HDAC inhibitors in primary OSCC. The results provide a new therapeutic strategy to minimize quiescence and target oral CSCs simultaneously.
- 1 June 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 4519-4530
Open AccessMitochondrial Stress–Mediated Targeting of Quiescent Cancer Stem Cells in Oral Squamous Cell Carcinoma
Introduction: Despite improved therapeutics in oral squamous cell carcinoma (OSCC), tumor cells that are either quiescent and/or endowed with stem cell–like attributes usually survive treatment and recreate tumor load at relapse. Through this study, we aimed strategically to eliminate these stem cell–like cancer cells using a combination drug approach. Methods: Primary cultures from 15 well–moderately differentiated OSCC were established, and the existence of cancer cells with stem cell–like characteristics using five cancer stem cell (CSC) specific markers — CD44, CD133, CD147, C166, SOX2 and spheroid assay was ascertained. Next, we assessed quiescence in CSCs under normal and growth factor–deprived conditions using Ki67. Among several gene signatures regulating quiescent cellular state, we evaluated the effect of inhibiting Dyrk1b in combination with topoisomerase II and histone deacetylase inhibitors in targeting quiescent CSCs. Multiple drug-effect analysis was carried out with CompuSyn software to determine combination-index values. Results: We observed that CD44+CD133+ showed the highest level of SOX2 expression. CSCs showed varying degrees of quiescence, and inhibition of Dyrk1b decreased quiescence and sensitized CSCs to apoptosis. In the drug-combination study, Dyrk1b inhibitor was combined with topoisomerase II and histone deacetylase inhibitors to target quiescent CSCs. In combination, a synergistic effect was seen even at a 16-fold lower dose than IC50. Furthermore, combined treatment decreased glutathione levels and increased ROS and mitochondrial stress, leading to increased DNA damage and cytochrome c in CSCs. Conclusion: We report marker-based identification of CSC subpopulations and synergy of Dyrk1b inhibitor with topoisomerase II and HDAC inhibitors in primary OSCC. The results provide a new therapeutic strategy to minimize quiescence and target oral CSCs simultaneously.